Initial Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Initial Therapeutics, Inc. - overview
Established
2020
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and co-founded by Jamie H. D. Cate, Spiros Liras (CEO), Brian Paegel, and Kevan Shokat in 2020, Initial Therapeutics, Inc. launched by Apple Tree Partners (ATP), operates as a biotechnology company that focuses on developing small-molecule medicine for difficult-to-drug protein targets to prevent the onset of diseases.
In April 2023, the firm raised USD 75 million in series A funding led by investor Apple Tree Partners. The company has developed an approach to disease intervention by targeting specific high-value protein targets using selective termination of protein synthesis (STOPS) in the exit tunnel of the ribosome. By leveraging this platform, STOPS, the company designs small-molecule medicines to halt pathogenic protein formation in the earliest stages. The company plans to utilize its April 2023 funding to support the discovery of new therapeutics.
Current Investors
Apple Tree Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.initialtx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.